Ovarian cancer is one of the most common gynecological malignancies among women in the world. It is the eighth most common cancer [1], with approximately 313,000 new cases diagnosed in women each year [2].
It can be difficult to detect in the early stages because there are no specific symptoms. The later it is diagnosed, the less favorable the prognosis. Meanwhile, the five-year survival rate varies significantly by stage at diagnosis. Patients with stage I disease have a survival rate of over 90%, while survival rates for stage III and IV disease drop to approximately 30% [3].
Many women who are faced with this challenging diagnosis have a chance to significantly improve outcomes by adding specialized medical care to their personalized treatment plan. Nowadays, multidisciplinary oncology teams are making sure that even in advanced stages, there is hope for a high quality of life.
Standard Treatment Protocols for Ovarian Cancer
Standard treatment strategies for ovarian cancer typically include surgery, chemotherapy, and, less commonly, radiation therapy [4]. The type of treatment the patient requires is determined by the stage at diagnosis, tumor spread, and the patient's overall health.
Surgery is considered the first step in the treatment of ovarian cancer in the early stages. The surgery involves the removal of the ovaries, fallopian tubes, uterus, and surrounding tissue with lymph nodes. When the cancer spreads further, cytoreductive surgery (debulking) is performed to remove as much of the tumor mass as possible.
Chemotherapy is a main systemic treatment option. It can be used after the surgery to destroy any remaining cancer cells or as a primary approach in advanced cases. Chemotherapy is administered in cycles, which can take several months and have aggressive side effects like hair loss, fatigue, low blood count, and nausea.
Radiation therapy isn’t the primary step of the treatment plan. It has limited effectiveness in the pelvic region due to the high risk of damaging healthy tissue. Radiation is only administered for patients who require palliative care to relieve symptoms such as pain or bleeding.
These standard approaches are the basis of ovarian cancer care, but they are usually associated with side effects that significantly negatively impact quality of life. Also, they still allow for the high risk of recurrence. The development of modern approaches aimed to resolve those problems and improve long-term outcomes.
Innovative Treatment Options for Ovarian Cancer
Modern oncology emphasizes a personalized treatment selection that can include both revolutionary and standard treatment options. Modern treatments aim to minimize side effects by targeting tumors precisely. Even in later stages, methods like interventional radiology procedures, dendritic cell therapy, HIPEC (hyperthermic intraperitoneal chemotherapy), and PIPAC (pressurized intraperitoneal aerosol chemotherapy) show remarkable results. Research indicates that these approaches are highly effective for patients with ovarian cancer, particularly when conventional treatments have failed.
Interventional Radiology for Ovarian Cancer
Interventional radiology (IR) offers a range of minimally invasive procedures that are increasingly valuable in oncology, especially for ovarian cancer patients with advanced or recurrent disease. They can be used on their own or as a complex part in an individualised treatment plan for patients at any stage of the disease. IR aims to deliver treatment directly to the cancer site, thereby sparing healthy tissues and reducing systemic side effects.
Thermal ablation is one of the most commonly used procedures as a minimally invasive approach for ovarian cancer. During thermal ablation, high temperatures are used to damage the cancer cells. There are two main approaches: high-intensity focused ultrasound (HIFU) and laser interstitial thermal therapy (LITT), where laser power is concentrated at the exact tumor site.
In recent years, these methods have been transforming the gynecologic oncology field and allow for achieving a local tumor control in up to 82% of patients with recurrent ovarian cancer [5]. Also, thermal ablation of secondary tumors improves progression-free survival in over 70% of patients.
Cryoablation is another IR technique that uses sub-zero temperatures to cause irreversible damage to cancer cells. It is showing promise in ovarian tumor treatment, particularly when combined with systemic therapy, indicating the extent of progression-free survival of above 80% of patients.
Above that, cryoablation is successfully used in combination with immunotherapy to treat metastasis in the lungs, especially in tumors resistant to systemic treatment. It can also be helpful when managing lesions within hard-to-reach locations in palliative scenarios.
Transarterial chemoembolization (TACE) is another safe, minimally invasive treatment specifically for liver metastases in ovarian cancer patients [6]. The procedure starts with the delivery of the drug directly to the blood vessel that supplies the tumor. It enables delivery of high concentrations directly to metastatic sites, reducing systemic side effects. Then an embolisation is performed, which traps the chemo inside the tumor, prolonging the exposure. TACE is a crucial option for patients with unresectable or treatment-resistant liver metastases, offering an increased local tumor control.
**DEBIRI = TACE, FOLFIRI = IV therapy; with DEBIRI, 90% of the patients have improved quality of life for 32 weeks [7]
Electrochemotherapy (ECT) Treatment for Ovarian Cancer
ECT uses electrical pulses to open cancer cell membranes. Once those cells are vulnerable, chemotherapy floods in at concentrations impossible to achieve with standard IV treatment – that is the breakthrough.
Doctors combine electro-chemotherapy with isolated perfusion for ovarian cancer patients who've failed conventional treatments. Electrodes positioned around the tumor, pulses delivered under anesthesia, and cancer cells become porous. Then, high-dose chemotherapy administered through arterial catheters during an isolated perfusion session – drug uptake increases exponentially. Electrochemotherapy in gynecological cancer exploits a fundamental difference: malignant cells are more vulnerable to electrical pulses than healthy tissue.
Side effects are minimal because treatment is localized, and patients recover quickly. The Booking Health website provides information about treatment access and the cost of electrochemotherapy at specialized centers. Electrochemotherapy cost is not always covered by insurance; it is better to clarify this in advance.
Electrochemotherapy Explained: Why This "New Kid on the Block" is Changing Cancer Treatment
Regional Chemotherapy for Ovarian Cancer
Published research on 107 ovarian cancer patients tells a remarkable story. Regional chemotherapy for ovarian cancer using hypoxic isolated abdominal perfusion achieved a median overall survival of 11.9 months in heavily pretreated, refractory cases – patients who'd failed multiple chemotherapy lines, ECOG performance status 2-3, poor prognosis [11].
Professor Karl R. Aigner developed this technique over 45 years. Hypoxic isolated abdominal perfusion works by isolating blood flow to the abdomen: balloon catheters positioned in the aorta and vena cava, high-dose chemotherapy injected as a bolus. Treatment conducted 15 minutes under hypoxic conditions – drugs exhibit augmented tumoricidal effect without oxygen, multiplying their normal cytotoxicity. After perfusion, chemofiltration removes drugs to prevent systemic toxicity.
Results: complete remission 17.3%, partial remission 51.7%, total clinical benefit 69%. Complete disappearance of ascites in 43% after just two perfusions – patients report dramatic relief of abdominal pain and distension. Quality of life improved in 74% of cases. Bone marrow suppression is minimal (WHO grade 1-2); no neutropenic fever or hand-foot syndrome has ever been observed [10].
Dendritic Cell Therapy for Ovarian Cancer
Dendritic cell vaccination is a new personalised immunotherapy that stimulates the patient's own immune system to target cancer cells. The process starts with collecting the patient's blood, then, in the laboratory, dendritic antigen-presenting cells are isolated and exposed to ovarian cancer cells. After the vaccine administration, dendritic cells begin to actively initiate the immune response.
Unlike the traditional approach, dendritic cell therapy minimizes damage to healthy cells and shows an 80% improvement in survival rates even in patients with advanced cancer, where other treatments have failed.
The foundation for this therapy was laid by Nobel Prize-winning scientist Dr. Ralph Steinman. He conducted evolutionary research that led to the development of a new cancer immunotherapy [9].
In the following interview with Professor Frank Gansauge, an expert in dendritic cell therapy, you can find out how these cells stimulate the anti-cancer response. Also, he discusses success stories of long-term remission and highlights how this therapy is enhanced when combined with other treatments.
Take a look at this video to discover more about the science, success, and future of dendritic cell vaccination.
Expert Insights from Prof. Gansauge: The Power of Dendritic Cell Therapy in Cancer Treatment
HIPEC (Hyperthermic Intraperitoneal Chemotherapy) for Ovarian Cancer
HIPEC (hyperthermic intraperitoneal chemotherapy) is an innovative procedure that is especially effective in patients with ovarian cancer in stages III and IV [12]. First, the surgeon carefully removes all the visible tumors. Then the heated chemotherapy drugs are administered directly into the abdominal cavity. The heat (41-43°C) increases drug delivery into malignant cells that remain after surgery. This procedure is highly effective and improves survival by up to 50%. Local use also limits side effects and makes it easier for patients to tolerate the treatment.
Here we bring to your attention the interview with Dr. Michael Lipp, Head of Abdominal and Colorectal Surgery at Asklepios Hospital Barmbek Hamburg. He explains how the HIPEC works, what the patients' criteria are, and how it's transforming ovarian cancer care.
Leading German Surgeon Dr. Lipp Reveals the Power of HIPEC in Cancer Treatment
PIPAC (Pressurized IntraPeritoneal Aerosol Chemotherapy) for Ovarian Cancer
PIPAC (pressurized intraperitoneal aerosol chemotherapy) is a minimally invasive, innovative treatment for advanced ovarian cancer. It is particularly valuable for patients with peritoneal metastases and those who are not candidates for open surgery or have not responded to traditional chemotherapy. PIPAC delivers chemotherapy as a pressurized aerosol via laparoscopy, a minimally invasive surgical procedure. This enables a better drug diffusion, deeper tissue penetration, and significantly reduced systemic side effects. Another benefit of PIPAC is that it can be repeated every 4-6 weeks, which is an important long-term option for advanced disease control.
It is shown that PIPAC can reduce tumor burden, relieve symptoms, and shrink tumors. This can further enable cytoreductive surgery and treatments such as HIPEC to be performed. PIPEC is also an advanced complementary or palliative approach to managing recurrent or inoperable ovarian cancer cases.
Comparative Analysis and Statistics for Ovarian Cancer
When evaluating ovarian cancer treatment options, it is necessary to compare the effectiveness, duration, and side effects of traditional and innovative methods..
| Characteristics/Therapy type | 2-Year Survival Rate | Response Rate | Duration | Side Effects |
|---|---|---|---|---|
| Standard Treatment | ~25% for advanced cancer | Less than 10% | Several cycles | Severe (nausea, fatigue, hair loss, immunosuppression, skin irritation) |
| Innovative Methods | ~60% for advanced cancer | 45-65% | Up to 4 sessions | Mild (localized discomfort) |
Ovarian Cancer Success Stories
When searching for ovarian cancer new treatment options, real-life success stories can motivate you to select the most effective treatments, including dendritic therapy, HIPEC, and PIPAC. These patients inspire hope and confidence for those battling this challenging disease. They also show the improved recovery rates and indicate that these innovative approaches can lead to remission even in advanced stages.
One of the stories is the case of Gretta Gasparian, who underwent 4 stage ovarian cancer treatment in Germany at LDG Laboratories under the care of Dr. Gansauge. When first diagnosed, she was not given a lot of options. Her family reached out to Booking Health for help and immediately received all the appropriate consultations, selected a personalised treatment plan, and received assistance with all the visa and travel documents.
With the supervision of Professor Gansauge, Gretta underwent dendritic cell immunotherapy, the most advanced and best ovarian cancer treatment in the world. She and her family received comprehensive support and excellent medical coordination from professional translators to travel managers, ensuring a smooth and stress-free experience.
Her story is a great example of effectivenes of dendritic therapy as well as how important it is to have experienced professionals by your side when seeking advanced cancer treatment.
Cost of Ovarian Cancer Treatment
The cost of treatment for ovarian cancer varies depending on the stage of the disease and the type of treatment that is recommended. Germany is famous for its transparent pricing and world-class medical care, including the most innovative cancer treatment procedures.
Treatment for stage 1 ovarian cancer can include surgery and local chemotherapy. Also, in the early ovarian cancer stages, laparoscopic procedures are the key surgical approaches, which are minimally invasive and cost-effective.
Stage 2 ovarian cancer management involves combining surgery and systemic chemotherapy or immunotherapy. The price depends on the complexity of the surgery and the chemotherapeutic regimen used.
When the disease is advanced, a more aggressive approach is required and can include a combination of cytoreductive surgery, dendritic cell therapy, and HIPEC to target metastases and affected lymph nodes.
| Treatment Method | GERMANY* | GB | USA |
|---|---|---|---|
| Standard Treatment | €80,000 - €150,000 full course | €90,000 - €165,000 full course | €100,000 - €180,000 full course |
| Innovative Methods | €25,000 - €60,000 full course | €70,000 - €120,000 full course | €100,000 - €150,000 full course |
*Prices may vary depending on the tumor size and the type of operation performed.
A Medical Journey: Every Step of the Way With Booking Health
Finding the best treatment strategy for your clinical situation is a challenging task. Being already exhausted from multiple treatment sessions, having consulted numerous specialists, and having tried various therapeutic interventions, you may be lost in all the information given by the doctors. In such a situation, it is easy to choose a first-hand option or to follow standardized therapeutic protocols with a long list of adverse effects instead of selecting highly specialized, innovative treatment options.
To make an informed choice and get a personalized cancer management plan, which will be tailored to your specific clinical situation, consult medical experts at Booking Health. Being at the forefront of offering the latest medical innovations for already 12 years, Booking Health possesses solid expertise in creating complex cancer management programs in each case. As a reputable company, Booking Health offers personalized stage 4 ovarian cancer treatment plans with direct clinic booking and full support at every stage, from organizational processes to assistance during treatment. We provide:
- Assessment and analysis of medical reports
- Development of the medical care program
- Selection of a suitable treatment location
- Preparation of medical documents and forwarding them to a suitable clinic
- Preparatory consultations with clinicians for the development of medical care programs
- Expert advice during the hospital stay
- Follow-up care after the patient returns to their native country after completing the medical care program
- Taking care of formalities as part of the preparation for the medical care program
- Coordination and organization of the patient's stay in a foreign country
- Assistance with visas and tickets
- A personal coordinator and interpreter with 24/7 support
- Transparent budgeting with no hidden costs
Health is an invaluable aspect of our lives. Delegating management of something so fragile yet precious should be done only to experts with proven experience and a reputation. Booking Health is a trustworthy partner who assists you on the way of pursuing stronger health and a better quality of life. Contact our medical consultant to learn more about the possibilities of personalized treatment with innovative methods for metastatic ovarian cancer with leading specialists in this field.
International Cancer Treatment: Patient Journeys with Booking Health
Frequently Asked Questions of Our Patients About Ovarian Cancer Treatment
Send request for treatmentOvarian cancer is detected through a pelvic exam with a transvaginal ultrasound. Also, tumor markers such as CA-125 are important. If there is suspicion of malignancy, further imaging (CT or MRI) and a biopsy may be performed to determine the type and stage.
The required tests are a transvaginal ultrasound and a CA-125 blood test. Sometimes, it is important to also test for BRCA1 and BRCA2 mutations, because they also show an increased risk of ovarian cancer.
Ovarian cancer is a woman's specific type of cancer that forms in the ovaries. It has three main types: epithelial tumors (most common), germ cell tumors, and stromal tumors. It is graded for the four stages based on its spread.
It is highly curable when diagnosed early, with stage I ovarian cancer having a 90% survival rate if the patient undergoes surgical removal and chemotherapy. If further tumor growth becomes more difficult to manage, but treatments like HIPEC and dendritic cell therapy offer improved survival and local tumor control.
Some of the early symptoms can include abdominal pain, bloating, urinary dysfunction, and sometimes digestive issues. The complaints are non-specific but become more pronounced over time, including pelvic pain, fatigue, and weight loss.
It is the 8th most commonly diagnosed cancer among females, with about 313,000 new cases diagnosed each year. The highest incidence is found in developed countries.
Ovarian cancer can significantly depend on genetic factors. Mutations in the BRCA1 and BRCA2 genes, as well as those with a family history of breast cancer, have an increased risk of developing ovarian cancer.
The baseline treatment is typically surgery and chemotherapy. However, with advancements in new therapies like PARP inhibitors and immunotherapy, such as dendritic cell therapy, the approach can shift toward more innovative options.
The stage is determined with the help of imaging techniques such as CT or MRI, or during surgery. Stage I is a small, localized tumor that can advance to stage IV if metastases spread to other organs. The early treatment is usually a combination of surgery and chemotherapy, and advanced cancers require a more complex approach with procedures like HIPEC, targeted therapy, and immunotherapy.
Ovarian cancer surgery usually involves the removal of the ovaries, fallopian tubes, and uterus. In advanced stages, chemotherapy or other techniques like PIPAC are used to reduce tumor size before open surgery or HIPEC.
Yes, targeted therapies, such as PARP inhibitors and monoclonal antibody medications, are available for ovarian tumors. They block the specific proteins that make the tumor unable to grow or divide. Also, treatments like dendritic cell vaccination provide your body with lifelong immunity against cancer.
Side effects of ovarian cancer treatments can be systemic, like nausea, hair loss, and fatigue. Modern localized therapies such as HIPEC tend to cause side effects like abdominal pain and fatigue, but these are generally less frequent and milder.
The early signs can include persistent bloating, pelvic pain, or changes in urination or appetite. These symptoms are nonspecific and can often limit diagnostic ability early on.
There are four stages of ovarian cancer, and ovarian cancer treatment by stage differs. In the early stages, a combination of surgery and chemo is usually used. When the desease progresses, a more personalised approach is required, including treatments like dendritic cell therapy, HIPEC, or PIPAC.
Early detection of ovarian cancer can often lead to a cure. At advanced stages, with modern therapies such as HIPEC or dendritic cell therapy, tumor growth can be managed, and remission can be achieved in some cases.
Germany is a center of modern technology and offers patients procedures such as HIPEC (heated chemotherapy), PIPAC (pressurized intraperitoneal aerosol chemotherapy), targeted therapy, immunotherapy, interventional radiology, and minimally invasive surgery. All of these procedures are individualised and carefully selected for each patient.
Yes, fertility preservation is a priority if the patient requests it. Cryopreservation of eggs or ovarian tissue before starting the treatment allows for possibity of future pregnancy.
Long-term management always requires follow-ups after receiving treatment. Patients are advised to be monitored every 3 to 6 months and undergo imaging, blood tests, and clinical exams in the first few years after treatment.
With Booking Health, international patients can access top ovarian cancer treatment centers in Germany, benefiting from visa assistance, translation services, guidance from English-speaking coordinators, and more — all to ensure a smooth treatment experience.
The cost of ovarian cancer treatment in Germany is based on how advanced your cancer is and what therapies your specific case requires. Standard approaches typically cost €80,000–150,000, while innovative methods cost around €25,000–60,000. In other developed countries like the UK and the USA, prices tend to be higher, and limited treatments are available.
What survival rates do innovative methods for ovarian cancer treatment demonstrate compared to standard ones?
According to research studies, a two-year survival rate in women with advanced ovarian cancer can be just about 25% when standard approaches are used. Modern therapies such as HIPEC, PIPAC, or dendritic cell therapy can increase survival by up to 60%.
Innovative approaches, including TACE, interventional radiology procedures, and dendritic cell therapy, achieve tumor response rates of 45–65% even in advanced or resistant cases. This is significantly higher than that of conventional chemotherapy, which shows an effect in less than 10% of patients.
Treatments such as PIPAC or interventional radiology procedures are performed over a few sessions, up to four. Another innovative therapy, dendritic cell vaccination, is a one-time injection that gives the possibility for lifelong immunity. In comparison, standard chemotherapy is given in several cycles over months or even years.
Innovative treatments, such as HIPEC, ECT, or PIPAC, are usually associated with mild local reactions such as discomfort or short-term pain. Unlike standard chemotherapy, they rarely cause nausea, hair loss, or immune suppression.
Stage 4 ovarian cancer treatment is personalized; doctors may combine tumor-reducing procedures, locoregional therapies, and immune-based approaches to control spread and support overall health – the plan is tailored to the patient’s condition and tumor characteristics.
The best results are achieved in centers experienced with advanced ovarian cancer. These hospitals coordinate surgeons, oncologists, and interventional specialists, adjusting therapy as the disease evolves (to maximize effectiveness and minimize complications).
Choose treatment abroad and you will for sure get the best results!
Authors:
This article was edited by medical experts, board-certified doctors Dr. Nadezhda Ivanisova, and Dr. Bohdan Mykhalniuk. For the treatment of the conditions referred to in the article, you must consult a doctor; the information in the article is not intended for self-medication!
Our editorial policy, which details our commitment to accuracy and transparency, is available here. Click this link to review our policies.
Sources:
[1] Giuseppe Caruso, S John Weroha, William Cliby. Ovarian Cancer: A Review. JAMA. 2025 Oct 14;334(14):1278-1291. doi: 10.1001/jama.2025.9495. [DOI] [PubMed]
[2] Anna S Avramenko, James M Flanagan. An epigenetic hypothesis for ovarian cancer prevention by oral contraceptive pill use. Clin Epigenetics. 2023 Oct 18;15(1):165. doi: 10.1186/s13148-023-01584-9. [DOI] [PubMed]
[3] Igor Aluloski, Mile Tanturovski, Rubens Jovanovic et al. Survival of Advanced Stage High-Grade Serous Ovarian Cancer Patients in the Republic of Macedonia. Open Access Maced J Med Sci. 2017 Nov 20;5(7):904–908. doi: 10.3889/oamjms.2017.215. [DOI] [PMC free article]
[4] Ashwin Chandra, Cima Pius, Madiha Nabeel et al. Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer Med. 2019 Sep 27;8(16):7018–7031. doi: 10.1002/cam4.2560. [DOI] [PMC free article]
[5] Frank Yuan, Sindy H Wei, Gottfried E Konecny et al. Image-Guided Percutaneous Thermal Ablation of Oligometastatic Ovarian and Non-Ovarian Gynecologic Tumors. J Vasc Interv Radiol. 2021 May;32(5):729-738. doi: 10.1016/j.jvir.2021.01.270. Epub 2021 Feb 16. [DOI] [PubMed]
[6] Giuseppe Cucinella, Mariano Catello Di Donna, Francesca De Maria et al. Chemoembolization, Radioembolization, and Percutaneous Ablation: New Opportunities for Treating Ovarian Cancer Liver Metastasis. Curr Treat Options Oncol. 2024 Nov;25(11):1428-1437. doi: 10.1007/s11864-024-01266-5. Epub 2024 Oct 19. [DOI] [PubMed]
[7] Fiorentini G et al Anticancer Res 2012;32:1387
[8] Attila Kovács, Peter Bischoff, Hathal Haddad et al. Long-Term Comparative Study on the Local Tumour Control of Different Ablation Technologies in Primary and Secondary Liver Malignancies. J. Pers. Med. 2022, 12(3), 430. doi: 10.3390/jpm12030430. [DOI]
[9] Roman Volchenkov, Florian Sprater, Petra Vogelsang, Silke Appel. The 2011 Nobel Prize in physiology or medicine. Scand J Immunol. 2012 Jan;75(1):1-4. doi: 10.1111/j.1365-3083.2011.02663.x. [DOI] [PubMed]
[10] Willemien J. van Driel, Simone N. Koole, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. January 17, 2018. N Engl J Med 2018;378:230-240 DOI: 10.1056/NEJMoa1708618. [DOI]
[11] Karl R Aigner, Sabine Gailhofer, Kornelia Aigner. Hypoxic isolated abdominal perfusion breaks through chemoresistance in recurrent FIGO stage IIIC and IV ovarian cancer. Mol Clin Oncol. 2021 Jun;14(6):129. doi: 10.3892/mco.2021.2291. Epub 2021 Apr 27. [DOI] [PubMed]
[12] Luigi Della Corte, Carmine Conte, Mario Palumbo et al. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): New Approaches and Controversies on the Treatment of Advanced Epithelial Ovarian Cancer-Systematic Review and Meta-Analysis. J Clin Med. 2023 Nov 9;12(22):7012. doi: 10.3390/jcm12227012. [DOI] [PubMed]
Read:
Treatment of stage 4 ovarian cancer in Germany
Article menu:
- Standard Treatment Protocols for Ovarian Cancer
- Innovative Treatment Options for Ovarian Cancer
- Comparative Analysis and Statistics for Ovarian Cancer
- Ovarian Cancer Success Stories
- Cost of Ovarian Cancer Treatment
- A Medical Journey: Every Step of the Way With Booking Health
- Frequently Asked Questions of Our Patients About Ovarian Cancer Treatment
Don't know where to start?
Contact Booking Health
